| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Department of Urology, Tohoku University School of Medicine Sendai 980-8574 [R. W., C. O., T. T., H. A., M. Sat., S. S., S. H., Y. A.]; and Department of Virology and Glycobiology, National Cancer Center, Research Institute, Tokyo 104-0045 [A. I., M. Sai.], Japan
We demonstrated previously (S. Kawamura et al., Int. J. Cancer, 94: 343347, 2001) that large amounts of ganglioside GM3 accumulate in superficial bladder tumor, compared with invasive bladder tumors and that exogenous GM3 inhibits the invasive potential of bladder tumor cells. To apply the GM3 overexpression system to bladder tumor therapy, direct evidence for the important role of GM3 in bladder tumor invasion must be obtained through transfer of the gene responsible for GM3 overexpression. To determine the most appropriate cancer cell line for elucidating the antitumor effect of ganglioside GM3 overexpression, the present study examined glycolipid composition, enzyme activity, and mRNA expression of the glycosyltransferases responsible for GM3 synthesis in the bladder tumor cell lines KK-47, J82, MGH-UI, YTS-1, and MBT-2. A murine bladder carcinoma cell line (MBT-2) was transfected with a GM3 synthase [(lactosylceramide
2,3-N-acetyl sialic acid transferase); sialyltransferase-I; SAT-I] cDNA, because this line does not naturally express GM3. Stable transfectants (MBT-2-SAT-I) that overexpressed GM3 were characterized by a reduced potential for cell proliferation, motility, invasion, and xenograft tumor growth, and an increase in the number of apoptotic cells. In the proportion of synthetic S phase, cells did not differ between MBT-2-SAT-I and mock-transfectant cells. These results suggest that the decreased proliferative potential related to GM3 overexpression was attributable to the increased number of apoptotic cells. Although details of the mechanism of apoptosis remain unclear, the overexpression of GM3 by gene transfer of SAT-I may present a novel therapeutic modality.
This article has been cited by other articles:
![]() |
H.-J. Choi, T.-W. Chung, S.-J. Kim, S.-Y. Cho, Y.-S. Lee, Y.-C. Lee, J.-H. Ko, and C.-H. Kim The AP-2{alpha} transcription factor is required for the ganglioside GM3-stimulated transcriptional regulation of a PTEN gene Glycobiology, May 1, 2008; 18(5): 395 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Noguchi, K. Kabayama, S. Uemura, B.-w. Kang, M. Saito, Y. Igarashi, and J.-i. Inokuchi Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells Glycobiology, July 1, 2006; 16(7): 641 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-J. Choi, T.-W. Chung, S.-K. Kang, Y.-C. Lee, J.-H. Ko, J.-G. Kim, and C.-H. Kim Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21WAF1 and p27kip1 by inhibition of PI-3K/AKT pathway Glycobiology, July 1, 2006; 16(7): 573 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sohn, Y.-S. Kim, H.-T. Kim, C.-H. Kim, E.-W. Cho, H.-Y. Kang, N.-S. Kim, C.-H. Kim, S. E. Ryu, J.-H. Lee, et al. Ganglioside GM3 is involved in neuronal cell death FASEB J, June 1, 2006; 20(8): 1248 - 1250. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ishimura, T. Takahashi, H. Nakagawa, S.-I. Nishimura, Y. Arai, Y. Horikawa, T. Habuchi, E. Miyoshi, A. Kyan, S. Hagisawa, et al. N-Acetylglucosaminyltransferase V and {beta}1-6 Branching N-Linked Oligosaccharides Are Associated with Good Prognosis of Patients with Bladder Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2506 - 2511. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hagisawa, C. Ohyama, T. Takahashi, M. Endoh, T. Moriya, J. Nakayama, Y. Arai, and M. Fukuda Expression of core 2 {beta}1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression Glycobiology, October 1, 2005; 15(10): 1016 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-W. Chung, H.-J. Choi, Y.-C. Lee, and C.-H. Kim Molecular mechanism for transcriptional activation of ganglioside GM3 synthase and its function in differentiation of HL-60 cells Glycobiology, March 1, 2005; 15(3): 233 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang and F. L. Kiechle Glycosphingolipids in Health and Disease Ann. Clin. Lab. Sci., January 1, 2004; 34(1): 3 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-Q. Wang, P. Sun, and A. S. Paller Ganglioside GM3 Inhibits Matrix Metalloproteinase-9 Activation and Disrupts Its Association with Integrin J. Biol. Chem., July 3, 2003; 278(28): 25591 - 25599. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Uemura, K. Kabayama, M. Noguchi, Y. Igarashi, and J.-i. Inokuchi Sialylation and sulfation of lactosylceramide distinctly regulate anchorage-independent growth, apoptosis, and gene expression in3LL Lewis lung carcinoma cells Glycobiology, March 1, 2003; 13(3): 207 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Prinetti, L. Basso, V. Appierto, M. G. Villani, M. Valsecchi, N. Loberto, S. Prioni, V. Chigorno, E. Cavadini, F. Formelli, et al. Altered Sphingolipid Metabolism in N-(4-Hydroxyphenyl)- retinamide-resistant A2780 Human Ovarian Carcinoma Cells J. Biol. Chem., February 14, 2003; 278(8): 5574 - 5583. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Paris, A. Morales, O. Coll, A. Sanchez-Reyes, C. Garcia-Ruiz, and J. C. Fernandez-Checa Ganglioside GD3 Sensitizes Human Hepatoma Cells to Cancer Therapy J. Biol. Chem., December 13, 2002; 277(51): 49870 - 49876. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |